Table 2 Overview of studies investigating bisphosphonates in models of breast cancer bone metastases
From: Anti-tumour activity of bisphosphonates in preclinical models of breast cancer
Breast cancer model | Bisphosphonate (dose) | Effect | Reference |
|---|---|---|---|
MDA-MB-231: intracardiac implantation | Risedronate (0.4, 4 and 40 μg/mouse/day) | Reduced osteolytic lesion volume Reduced intra-osseous tumour volume Increased bone-associated soft tissue tumour burden | [45] |
MDA-MB-231: intracardiac implantation | YH529 (0.2, 2 and 20 μg/mouse/day) | Reduced osteolytic lesion volume Reduced intra-osseous tumour volume Increased bone-associated soft tissue tumour burden after 0.2 and 2 μg doses, decreased after 20 μg | [46] |
4T1/luc: bone metastases | Zoledronic acid (0.5 and 5 μg/mouse) | Reduced osteolytic lesion volume Increased tumour cell apoptosis | [51] |
MDA-MB-231: intracardiac implantation | Ibandronate (4 μg/mouse/day, 7 days) | Reduced osteolytic lesion volume Reduced intra-osseous tumour volume | [49] |
MDA-MB-231: injected in femoral artery, nude rats | Ibandronate (10 μg/kg/day) | Reduced osteolytic lesion volume Reduced intra-osseous tumour volume | [50] |
MDA-MB-231/luc: intracardiac and intra-osseous implantation | Olpandronate (1.6 μm/kg/day, 18 days/40 days) Pamidronate (1.6 μm/kg/day, 40 days) | Olpandronate: reduced osteolytic lesion volume and reduced intra-osseous tumour volume Pamidronate: reduced lytic lesions and intra-osseous tumour growth after intratibial implantation No effect of BPs on bone-associated soft tissue burden | [47] |
B02: generates bone metastases following intravenous injection | Zoledronic acid (3 and 7 μg/kg/day; 20 and 50 μg/kg/week; 100 μg/kg 1×) Clodronate (530 μg/kg/day) | Clinically relevant doses used No effect of a single dose of zoledronic acid Weekly and daily administration of zoledronic acid reduced osteolysis and intra-osseous tumour growth Daily clodronate less effective compared to zoledronic acid | [52] |